Pociredir (FTX-6052)

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biotech company with a mission to develop small molecule therapies that treat the root cause of genetically defined rare diseases by modulating gene expression. Its core achievement is the development of a proprietary functional genomics platform that identifies master regulator proteins to create targeted treatments. The company's strategy focuses on high-unmet-need disorders with clear genetic drivers, such as FSHD and sickle cell disease, leveraging regulatory pathways for rare diseases. Fulcrum's lead asset, losmapimod for FSHD, has completed Phase 3 trials, positioning the company for a potential near-term regulatory filing and commercialization.

Therapeutic Areas